Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial
Li W, Onishi N, Newitt D, Gibbs J, Wilmes L, Jones E, Joe B, Sit L, Yau C, Chien A, Price E, Albain K, Kuritza T, Morley K, Boughey J, Brandt K, Choudhery S, Clark A, Rosen M, McDonald E, Elias A, Wolverton D, Fountain K, Euhus D, Han H, Niell B, Drukteinis J, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Asare S, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Berry D, DeMichele A, Abe H, Sheth D, Edmiston K, Ellis E, Ha R, Wynn R, Crane E, Dillis C, Nelson M, Church A, Isaacs C, Khan Q, Oh K, Jafarian N, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Sheth P, Hovanessian-Larsen L, Eghtedari M, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Goudreau S, Brown T, Esserman L, Hylton N. Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial. Cancer Research 2020, 80: pd9-04-pd9-04. DOI: 10.1158/1538-7445.sabcs19-pd9-04.Peer-Reviewed Original ResearchI-SPY 2 TRIALFunctional tumor volumeTumor volume progressionTumor progressionNon-pCRI-SPYTumor volumeHER2 subtypeVolume progressionCancer subtypesTumour progressorsEvaluate MRI changesI-SPY 2Triple negative subtypeHER2+ tumorsHigh-risk patientsNegative predictive valueBreast cancer subtypesEnhancement post-contrastTime pointsNumbers of patientsInsufficient image qualityTreatment time pointsPost-NACPre-NACAbstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
Li W, Onishi N, Newitt D, Harnish R, Jones E, Wilmes L, Gibbs J, Price E, Joe B, Chien A, Berry D, Boughey J, Albain K, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Yau C, Asare S, DeMichele A, Goudreau S, Abe H, Sheth D, Wolverton D, Fountain K, Ha R, Wynn R, Crane E, Dillis C, Kuritza T, Morley K, Nelson M, Church A, Niell B, Drukteinis J, Oh K, Jafarian N, Brandt K, Choudhery S, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Eghedari M, Sheth P, Hovanessian-Larsen L, Rosen M, McDonald E, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Esserman L, Hylton N. Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI. Cancer Research 2020, 80: p6-02-01-p6-02-01. DOI: 10.1158/1538-7445.sabcs19-p6-02-01.Peer-Reviewed Original ResearchEffect of background parenchymal enhancementFunctional tumor volumeBackground parenchymal enhancementLower background parenchymal enhancementNeoadjuvant chemotherapyTumor volumeParenchymal enhancementDynamic contrast-enhancedHR-/HER2Treatment time pointsContralateral breastPatient cohortTime pointsHigher background parenchymal enhancementI-SPY 2 TRIALWeeks of neoadjuvant chemotherapyLocally advanced breast cancerMRI examsHormone receptorsHR-/HER2- subtypeMR tumor volumesPrediction of pCRNeoadjuvant chemotherapy regimensEnhancement thresholdHR-/HER2+